Table 3 presents the baseline characteristics of breast cancer patients across the cohorts as follows: EFP with 45 cycles, LFP with 28 cycles, LP with 22 cycles, and DuoStim with 23 cycles. Consistent with the overall cohort findings, no significant differences were observed in age, FSH levels, AMH levels or complication rates among the groups. However, the DuoStim group showed a significantly lower number of AFC compared to the EFP, LFP and LP groups (adjusted p < 0.05, <0.05, and <0.01, respectively, FDR). This evidence concerns the gene AMH and breast cancer.